Torrevieja

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy SCIT in people aged 12 to 65 who have allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The study focuses on patients sensitized to specific house dust mites, Dermatophagoides pteronyssinus andor Dermatophagoides farinae. This is a phase 3, double-blind, placebo-controlled, randomized trial conducted at multiple centers. Participants will be randomly assigned to one of three groups two receive different doses of SCIT 10,000 TUmL or 30,000 TUmL of allergenic extract, and one receives a placebo injection without active ingredients. Treatment lasts for one year, with doses administered subcutaneously. The study compares the two active treatment groups to the placebo group to determine which dose may be more effective and safe. During the trial, participants will be closely monitored for symptoms and medication use, assessed by the Combined Symptoms and Medication Score CSMS over 12 months. Researchers will also track medication-free days, symptom-free days, quality of life related to asthma and rhinitis, adverse events, and immunological responses. Participants will log symptoms and medication use via smartphone. Safety and treatment effects will be evaluated throughout the study period.

The trial investigates the use of the probiotic supplement Bioithas WOMAN4 as an additional treatment alongside antifungal medication for women with clinically suspected vulvovaginal candidiasis VVC. This open-label, randomized clinical trial includes a control group and focuses on evaluating symptom improvement and microbiological changes over a 4-week treatment period. The study aims to compare outcomes between women receiving only antifungal treatment and those also taking the probiotic supplement. Participants will be randomly assigned to either the treatment group, which receives the probiotic supplement in addition to prescribed antifungal therapy, or the control group, which receives antifungal treatment alone. The probiotic is provided as a bottle containing 30 capsules, taken during the 4-week intervention. The study includes two on-site visits a baseline visit where clinical data and vaginal samples are collected, and a final visit at week 4, where the same assessments are repeated, including symptom scoring and microbiological cultures. During the study visits, researchers will collect demographic and gynecological history, record symptoms such as vaginal discharge, itching, burning, irritation, and pain during intercourse, and measure vaginal pH. Vaginal samples will be cultured to detect Candida and assess Lactobacillus levels. Treatment adherence in the probiotic group will be monitored by capsule counts. The main outcome measured is the difference in symptom absence after 4 weeks between groups, along with secondary outcomes like symptom scores, microbiological culture results, and adherence. Any adverse events and additional treatments during follow-up will also be recorded.

Researchers are conducting a national, multicenter observational study called SOGUG-PRINCIS to collect and analyze data on patients with genitourinary cancers treated with recently approved drugs under routine clinical practice in Spain. This study is both retrospective and prospective, aiming to validate real-world effectiveness of these drugs and support future funding decisions. It will serve as a registry where new subprojects will open whenever new drugs receive authorization. The study follows patients who have started treatment with specific drugs funded by the Spanish National Health System, including darolutamide combined with androgen deprivation therapy and docetaxel for hormone-sensitive prostate cancer, adjuvant nivolumab after surgery for urothelial carcinoma, and enfortumab vedotin for urothelial carcinoma. All treatments follow their approved dosing and administration guidelines and standard clinical practice. Participants progress will be monitored through routine data collection to evaluate outcomes such as progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after starting treatment. Data will be gathered from patients treated at participating centers, with follow-up continuing as per routine care. The study does not intervene in treatment decisions, which are made independently before enrollment.

Researchers are evaluating the effect of seltorexant as an add-on treatment to antidepressants in adults and elderly people with major depressive disorder who also have insomnia symptoms and have not responded well to their current antidepressant therapy with SSRIs or SNRIs. This Phase 3 study aims to understand how well seltorexant works, its safety, and its ability to maintain improvement compared with a placebo. Participants in part 1 of the study will receive either seltorexant or a matching placebo once daily for 6 weeks, alongside their usual SSRI or SNRI antidepressant. Those who complete part 1 and meet criteria for part 2, plus new participants entering directly into part 2, will receive seltorexant during an open-label induction and stabilization phase. Participants who respond well will then enter a double-blind maintenance phase, receiving either seltorexant or placebo daily, continuing their baseline antidepressant throughout. During the study, participants will be monitored through rating scales measuring depression severity, sleep disturbance, and patient health questionnaires at baseline and specified days up to two years and ten months. Researchers will assess changes in depression symptoms and time to relapse, along with safety and tolerability. Participants will be followed through treatment phases and post-treatment periods to evaluate the maintenance of effects and overall safety.

Researchers are observing patients with coronary artery disease who are being treated with the SELUTION SLRTM sirolimus-coated balloon. This study follows a group of real-world patients in multiple centers internationally to evaluate how this device performs in treating native coronary artery lesions and in-stent restenosis, focusing on its safety and effectiveness. The main goal is to assess major adverse cardiovascular events over 12 months, including death, heart attacks, or need for further treatment. Participants receive treatment with the SELUTION SLRTM device as decided by their doctors, targeting lesions in native vessels, coronary grafts, or restenosis cases. This is an observational study without a control group, meaning all participants receive the treatment as part of routine care. The study tracks outcomes over a year following the use of the device to gather real-world data. Throughout the study, participants undergo clinical follow-up to monitor cardiovascular events, device-related complications, and other health measures. Researchers collect data on major adverse cardiovascular events, target lesion revascularization, and specific composite endpoints at 12 months. Safety and success of the procedure are also recorded, with follow-ups continuing up to 12 months after treatment. Participation spans about one year from treatment to final assessments.